Investor's Business Daily: UB prof's drug begins Phase 1 human testing

Release Date: November 27, 2007 This content is archived.

Print

An article in Investor's Business Daily reports Kinex Pharmaceuticals LLC has begun Phase 1 human testing of its new drug, KX2-391, and quotes David Hangauer, associate professor of chemistry and cofounder of Kinex, who said, "What's remarkable about this compound is that, in preclinical testing, it has worked against every cancer and in every animal model."

Media Contact Information

John Della Contrada
Vice President for University Communications
521 Capen Hall
Buffalo, NY 14260
Tel: 716-645-4094 (mobile: 716-361-3006)
dellacon@buffalo.edu
Twitter: @UBNewsSource